Early detection of hepatocellular carcinoma through surveillance using biomarkers.
作者信息
Gish Robert G
机构信息
Robert G. Gish Consultants, LLC San Diego, California.
出版信息
Gastroenterol Hepatol (N Y). 2014 Feb;10(2):121-3.
Abstract
摘要
相似文献
1
Early detection of hepatocellular carcinoma through surveillance using biomarkers.
Gastroenterol Hepatol (N Y). 2014 Feb;10(2):121-3.
2
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis.
Biomark Med. 2015;9(12):1343-51. doi: 10.2217/bmm.15.100. Epub 2015 Nov 18.
3
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.
World J Hepatol. 2015 Feb 27;7(2):139-49. doi: 10.4254/wjh.v7.i2.139.
4
Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
Biomark Med. 2007 Aug;1(2):273-84. doi: 10.2217/17520363.1.2.273.
5
Current Practice of Hepatocellular Carcinoma Surveillance.
Acta Med Indones. 2018 Oct;50(4):353-360.
6
Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation.
Drug Discov Ther. 2017;11(3):168-169. doi: 10.5582/ddt.2017.01036.
7
Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
BMC Cancer. 2018 Sep 24;18(1):915. doi: 10.1186/s12885-018-4827-2.
8
Hepatocellular carcinoma tumour markers: current role and expectations.
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):843-53. doi: 10.1016/j.bpg.2014.07.018. Epub 2014 Aug 22.
9
[Research progress of serum biomarkers for early screening of hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):308-312. doi: 10.3760/cma.j.cn501113-20210402-00158.
10
Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived?
Hepatobiliary Surg Nutr. 2014 Dec;3(6):410-4. doi: 10.3978/j.issn.2304-3881.2014.07.06.
引用本文的文献
1
α-Fetoprotein, α-Fetoprotein-L3, and Des-γ-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk.
Gastro Hep Adv. 2023 Dec 7;3(3):316-325. doi: 10.1016/j.gastha.2023.11.018. eCollection 2024.
2
Biomarker in Hepatocellular Carcinoma.
Indian J Surg Oncol. 2024 May;15(Suppl 2):261-268. doi: 10.1007/s13193-023-01858-x. Epub 2024 Jan 2.
3
Electrochemical Cellulase-Linked ELASA for Rapid Liquid Biopsy Testing of Serum HER-2/.
ACS Meas Sci Au. 2023 Apr 14;3(3):226-235. doi: 10.1021/acsmeasuresciau.2c00067. eCollection 2023 Jun 21.
4
Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
Hepatol Commun. 2022 Apr;6(4):679-691. doi: 10.1002/hep4.1847. Epub 2021 Nov 19.
5
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
BMC Gastroenterol. 2019 Oct 21;19(1):167. doi: 10.1186/s12876-019-1082-1.
6
Studying the Impact of Golgi Protein 73 Serving as a Candidate Biomarker in Early Diagnosis for Hepatocellular Carcinoma among Saudi Patients.
Asian Pac J Cancer Prev. 2019 Jan 25;20(1):215-220. doi: 10.31557/APJCP.2019.20.1.215.
7
GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Tumour Biol. 2016 Sep;37(9):12571-12577. doi: 10.1007/s13277-016-5127-6. Epub 2016 Jul 5.
8
High-Throughput Analysis and Automation for Glycomics Studies.
Chromatographia. 2015;78(5-6):321-333. doi: 10.1007/s10337-014-2803-9. Epub 2014 Nov 16.
9
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.
World J Hepatol. 2015 Jan 27;7(1):7-27. doi: 10.4254/wjh.v7.i1.7.
本文引用的文献
1
Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.
Dig Dis Sci. 2013 Aug;58(8):2406-12. doi: 10.1007/s10620-013-2661-6. Epub 2013 Apr 18.
2
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
Gastroenterology. 2010 Feb;138(2):493-502. doi: 10.1053/j.gastro.2009.10.031. Epub 2009 Oct 20.
3
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
Cancer Biomark. 2007;3(2):79-87. doi: 10.3233/cbm-2007-3202.
4
Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.
Clin Gastroenterol Hepatol. 2006 Jan;4(1):111-7. doi: 10.1016/s1542-3565(05)00855-4.
Zotero 插件